You are indeed correct that it requires many large and high quality studies. Cannalogue’s platform is actually designed not only to be a marketplace, but also a digital research engine that could conduct studies.
Cannalogue actually applied for a research licence to study medical cannabis and COVID19. Health Canada was looking to expedite the licence as well. The difficulty was in finding LPs with a) GMP certification and b) pre-clinical toxicology data.
Cannalogue’s platform and protocols would reduce the costs significantly compared to the typical costs. University partners have also been arranged. The funding would come from sponsors or the government.
The challenge has been securing product with the requirements above.